Consider the arithmetic of elegance: NUANCE’s stake now rests at 314,208 shares, a $20.85 million bauble that adorns just 2.1% of their $982.15 million portfolio. To sell thirty-eight million may be considered prudent; to retain twenty seems positively romantic. The position’s contraction from 5.6% to 2.12% of AUM reads like a financial villanelle – each line a measured diminuendo.
By the somber decree of legal documents, the fund’s representatives, ensnared in bureaucratic coils, disposed of a quantity of shares that collectively represented a mere fragment-3.3%-of their prior grasp, halving the apparent stakes in a game governed by precios and timing no one fully understands. The transaction, executed within the opaque corridors of the quarter’s pricing averages, concluded at a figure nearing eight million dollars, a sum that, like most things in this labyrinth, appears to fluctuate wildly between significance and insignificance, especially once cloaked in the fog of market sentiment.
The fund, that ever-eager collector of stocks, quietly revealed it bought a hefty chunk of Dentsply during the third quarter ending September 30, 2025. Multiplied by a million, it means gaining more than 1.5 million shares, pushing their total to over 1.5 million, worth roughly $19.34 million at the close of that financial quarter. Now, those shares make up about 13.5% of Brickwood’s U.S. equity meatloaf. An impressive appetite for a company with a track record that would give even the most optimistic investor pause.
The Chicago-based alchemists at Readystate recently filed Form 13F with the SEC, revealing their new position in Workiva. This constitutes 2.43% of their U.S. equity holdings – a figure that sounds more impressive until you realize they hold 301 other securities. Like a gambler spreading chips across a rigged roulette table, they’ve bet 1.36% of their $2.35 billion AUM on a software outfit whose stock has been playing dead man’s float against the S&P 500.
The transaction, recorded with the solemnity of a coroner’s report, reduced the fund’s exposure by precisely 100,461 shares during the third quarter. This surgical reduction left 245,581 shares trembling in the cold embrace of market forces, now valued at $14.6 million-a sum that would soon prove more theoretical than actual.
The Vanguard High Dividend Yield ETF, like a hapless bureaucrat caught in the sprawling web of financial markets, tracks an index more expansive than its rival’s, a sprawling landscape of American companies, each clinging to a forecast of above-average dividend yield. The mere thought of these stocks-their hands outstretched for the promise of higher returns-becomes a hollow echo in the wind. Its fee, a meager 0.06% as of October 31, 2025, stands in eerie contrast to NOBL’s 0.35%, an additional burden for those seeking returns but finding themselves entrapped by bureaucracy. Herein lies the dilemma: those with a mind for the immediate, for the costs that bind them, may find comfort in VYM’s less demanding toll. But is it comfort, or simply a continuation of the eternal chase for more? A pursuit unending, as both seek the same elusive dividend yield.
The filing, released under the watchful eye of Thursday’s market gods, reveals Essex now holds 194,343 shares of Globalstar, valued at $7.1 million by quarter’s end. This positions the satellite sorcerer’s stock as 1.1% of Essex’s $653.4 million portfolio of U.S. equity holdings-a sliver of cosmic string in their grand tapestry of investments.
HODL, with its 0.20% expense ratio, feels like the frugal cousin who still lives at home, while IBIT’s 0.25% fee reads like a dinner invitation to a five-star restaurant. Yet AUM tells a different story: IBIT’s $88 billion is the financial equivalent of a small country’s GDP. One might assume scale brings lower fees, but as we’ll see, the real world rarely obeys logic.
The transaction, involving 150,000 shares representing 4.1% of the fund’s U.S. equity assets, places Dycom firmly in the category of “not entirely negligible” within Bornite’s 35-position portfolio. It’s the sort of investment that suggests careful calculation, or perhaps a particularly persuasive pitch over a liquid lunch.
And yet, beneath the surface of their impressive statistics lies the bitter truth-an ever-present reminder of the paradox of growth. Genius Sports, a titan in its field, relentlessly scales upward, all the while clinging to the very data it peddles, like an addict to the needle of its own invention. They sell the very thing that might, someday, strip them bare of all pretense: information.